… Hani Almoallim reports grants and non-financial support from Alzaidi Chair of Research in
Rheumatic Diseases, and grants from Pfizer Pharmaceutical, during the conduct of the study. …

Background In contrast to most regions of the world where a decline of the HIV epidemic
can be seen, data from the Middle East and North Africa (MENA) region suggests increasing …

Background Even after achieving tremendous advances in diagnosis and treatment of
rheumatoid arthritis (RA), many of the patients undergo delays in diagnosis and initiation of …

The status of rheumatoid arthritis (RA) in Saudi Arabia (SA) was examined from various
perspectives based on a systematic literature review and the authors’ personal experiences. In …

Objectives Rheumatoid arthritis (RA) is often not diagnosed or treated quickly enough to
alter outcomes. We aimed to evaluate the lag times from disease onset to first clinical …

Objectives: To delineate the clinical features and outcomes of dengue infection and to guide
clinician of early diagnosis and identification of risks factors for dengue hemorrhagic fever. …

Anti-tumor necrosis factor-alpha induced lupus (ATIL) represents a major diagnostic and
therapeutic challenge. Most cases of ATIL are caused by infliximab, followed by etanercept and …

Objective Early diagnosis and initiation of treatment for inflammatory arthritis can greatly
improve patient outcome. We aimed to provide standardized and validated criteria for use by …

Objective Conventional treatment of systemic lupus erythematosus (SLE) and lupus nephritis
(LN) is associated with damage accrual, hence increased morbidity rate. Off-label use of …

Estimates of the global prevalence of rheumatoid arthritis (RA) range from 0.24 to 1%, but
vary considerably around the globe. A variation in RA prevalence is also expected across …